Kymera Therapeutics Inc
(NAS:KYMR)
$
50.05
-1.84 (-3.55%)
Market Cap: 3.24 Bil
Enterprise Value: 2.90 Bil
PE Ratio: 0
PB Ratio: 3.63
GF Score: 47/100 Kymera Therapeutics Inc at Credit Suisse Healthcare Conference Transcript
Nov 09, 2022 / 05:50PM GMT
Release Date Price:
$27.83
(-8.24%)
Jin Law;dit Suisse AG
CrÃ;Research Division - Senior Analyst
© -
Okay. We're going to get started. My name is Rich Law. I'm a senior biotech analyst at CS. I'd like to welcome our -- Kymera for next fireside chat. We're joined by Nello Mainolfi, CEO. Nello, welcome.
Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director
Thanks, Richard. Thanks for the invite.
Jin Law;dit Suisse AG
CrÃ;Research Division - Senior Analyst
© -
So before we jump into Q&A, any opening remarks from you?
Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director
Yes. So first, thanks for the invitation. Beautiful location. Luckily, today is a good day.
I just want to remind everybody, Kymera is a company focused on taking targeted protein degradation and building a fully integrated commercial-stage biotech in a disease-agnostic and technology-agnostic manner. Obviously, we've
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot